Natera appoints Steve Chapman CEO, Robert Schueren COO

Natera appointed Steve Chapman as CEO, and Robert Schueren as COO effective January 7, 2019. Previously, Chapman was the company’s COO and will succeed Matthew Rabinowitz, Natera co-founder and CEO. Rabinowitz will remain involved as Executive Chairman focusing on the company’s long-term business strategy and technology innovation. Since joining Natera in 2010, Chapman has had roles ranging from Vice President of Sales, to Senior Vice President of Commercial, to Chief Commercial Officer and most recently COO. Chapman was previously at Genzyme Genetics. Schueren has served in executive leadership roles at companies including IntegenX, Agilent Technologies, and Genentech.
https://thefly.com/landingPageNews.php?id=2842761

Fate Therapeutics named a 2019 top pick at Piper Jaffray

Piper Jaffray analyst Edward Tenthoff said Fate Therapeutics remains a top pick into 2019 and he reiterated his Overweight rating and $23 price target on the stock, stating that he is “most excited” about Fate’s “disruptive” pipeline of 10 iNK and iT cell induced Pluripotent Stem Cell candidates. The FDA accepted the IND for Fate’s first iNK candidate and he expects initial FT500 data this year to validate Fate’s broader iPSC platform, Tenthoff added.
https://thefly.com/landingPageNews.php?id=2842773

Genomic Health initiated at Needham

Genomic Health initiated at Needham  Genomic Health initiated with a Strong Buy at Needham. analyst Stephen Unger initiated Genomic Health with a Strong Buy rating and $86 price target, stating that he sees significant EPS upside potential from the commercialization of its expanding portfolio of molecular diagnostic testing services and a focus on profits.
https://thefly.com/landingPageNews.php?id=2842783

Danaher initiated at Needham

Danaher initiated with a Buy at Needham. Needham analyst Stephen Unger started Danaher with a Buy rating and $114 price target. The company is one of only two major consolidators within the Life Science Tools sector, which continues to deliver “strong secular growth,” says the analyst.
https://thefly.com/landingPageNews.php?id=2842785

Myriad Genetics initiated at Needham

Myriad Genetics initiated at Needham  Myriad Genetics initiated with a Strong Buy at. Needham analyst Stephen Unger started Myriad Genetics with a Strong Buy rating and $36 price target. The analyst believes the company’s expanding portfolio of molecular diagnostic testing services and an increased focus on profit improvement can drive “significant” earnings upside.
https://thefly.com/landingPageNews.php?id=2842791

NeoGenomics initiated at Needham

NeoGenomics initiated with a Buy at Needham. Needham analyst Stephen Unger started NeoGenomics with a Buy rating and $14 price target.
https://thefly.com/landingPageNews.php?id=2842795

Humana backs FY18 adjusted EPS view of approximately $14.40, consensus $14.43

For the year ended December 31, 2018, Humana’s management expects to reaffirm its GAAP guidance of $11.96 in diluted earnings per common share, or approximately $14.40 in adjusted earnings per common share. This guidance is consistent with the guidance issued in Humana’s press release dated November 7, 2018 and reaffirmed on November 28, 2018.

https://thefly.com/landingPageNews.php?id=2842799